Rising Pharmaceuticals, Inc. has announced the commercial launch of Edetate calcium disodium injection. Despite a current shortage of this product in the U.S., Rising’s version remains available.
Rising Pharmaceuticals, Inc. has announced the availability of Edetate calcium disodium injection, which is used to reduce blood lead levels and treat lead poisoning and lead encephalopathy in both children and adults.
David Picard, Executive Vice President for Institutional Markets at Rising, stated, “Rising’s Edetate calcium disodium injection offers a crucial option for healthcare providers treating lead poisoning. Our commitment to maintaining product availability during shortages underscores our dedication to supporting patient care.”
Product Details:
- Edetate Calcium Disodium Injection, USP
- Form: 5 mL single-dose vial
- Concentration: 200 mg/mL (1000 mg per vial)
- Packaging: Boxes of 5 vials
- NDC: 64980-588-51
Wholesale Item Numbers:
- Cardinal: 5855416
- Cencora: 10291753
- McKesson: 2830826
- Morris Dickson: 296285
For full prescribing information and labels, visit DailyMed.
About Rising Pharmaceuticals, Inc.
Rising Pharmaceuticals, Inc. is a major provider of generic and specialty-branded pharmaceuticals in the U.S. With over 182 commercialized generic medicines and 620 active SKUs, Rising boasts one of the largest portfolios in the U.S. market. The company focuses on the development, regulation, and commercialization of pharmaceuticals while outsourcing manufacturing to strategic partners, supplying nearly 9 billion doses annually through its global network.
